Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab
Digestive and Liver Disease · 2024
DOI: 10.1016/j.dld.2023.10.027 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Paula Sousa und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Viseu-Tondela Hospital Centre, Viseu, Portugal. Hauptthemen laut MEDLINE: Infliximab, Crohn Disease, Leukocyte L1 Antigen Complex, C-Reactive Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: The emergence of new treatments the inflammatory bowel diseases (IBD) raised questions regarding the role of older agents, namely thiopurines. AIMS: To clarify the benefits of combination treatment with thiopurines on Crohn's disease (CD) patients in the maintenance phase of infliximab. METHODS: In this analysis of the 2-year prospective multicentric DIRECT study, patients were assessed in terms of clinical activity, faecal calprotectin (FC), C-reactive protein (CRP), and infliximab pharmacokinetics. A composite outcome based on clinical- and drug-related items was used to define treatment failure. RESULTS: The study included 172 patients; of these, 35.5 % were treated with combination treatment. Overall, 18 % of patients achieved the composite outcome, without statistically significant differences between patients on monotherapy and on combination treatment (21.6% vs 11.5 %, p = 0.098). Median CRP, FC, and infliximab pharmacokinetic parameters were similar in both groups. However, in the sub-analysis by infliximab treatment duration, in patients treated for less than 12 months, the composite outcome was reached in fewer patients in the combination group than in the monotherapy group (7.1% vs 47.1 %, p = 0.021). CONCLUSION: In CD patients in maintenance treatment with infliximab, combination treatment does not seem to have benefits over infliximab monotherapy beyond 12 months of treatment duration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Viseu-Tondela Hospital Centre, Viseu, Portugal.
- Department of Gastroenterology, Garcia da Orta Hospital, Almada, Portugal.
- Department of Gastroenterology, Braga Hospital, Braga, Portugal.
- Department of Gastroenterology, Porto Hospital University Centre, Porto, Portugal.
- Department of Gastroenterology, IPOLFG, EPE, Lisbon, Portugal.
- Department of Gastroenterology, Algarve Hospital University Centre - Portimão Unit, Portimão, Portugal; ABC - Algarve Biomedical Center, University of Algarve, Faro, Portugal.
Zitieren
APA
Sousa, P., Patita, M., Arroja, B., Lago, P., Rosa, I., de Sousa, H. T., Ministro, P., Mocanu, I., Vieira, A., Castela, J., Moleiro, J., Roseira, J., Cancela, E., Portela, F., Correia, L., Santiago, M., Dias, S., Alves, C., Afonso, J., …, & Magro, F. (2024). Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2023.10.027
Vancouver
Sousa P, Patita M, Arroja B, Lago P, Rosa I, de Sousa HT, et al. Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2023.10.027
BibTeX
@article{Sousa2024,
author = {Sousa, Paula and Patita, Marta and Arroja, Bruno and Lago, Paula and Rosa, Isadora and de Sousa, Helena Tavares and Ministro, Paula and Mocanu, Irina and Vieira, Ana and Castela, Joana and Moleiro, Joana and Roseira, Joana and Cancela, Eugenia and Portela, Francisco and Correia, Luis and Santiago, Mafalda and Dias, Sandra and Alves, Catarina and Afonso, Joana and Dias, Claudia Camila and Magro, Fernando},
title = {Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab},
journal = {Digestive and Liver Disease},
year = {2024},
doi = {10.1016/j.dld.2023.10.027}
}
EUVIMED